FDA Drug Recalls

Recalls / Class II

Class IID-1297-2020

Product

Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vials (NDC 63323-162-03), 25 x 2 mL Single Dose Vials per tray (NDC 63323-162-02); For IM use only, Not for IV use, Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Brand name
Ketorolac Tromethamine
Generic name
Ketorolac Tromethamine
Active ingredient
Ketorolac Tromethamine
Route
Intramuscular, Intravenous
NDCs
63323-161, 63323-162
FDA application
ANDA075784
Affected lot / code info
Lot #: 6119229, 6119273, Exp 06/2020; 6119843, Exp 09/2020; 6121115, Exp 02/2021; 6121451, 6121452, 6121496, Exp 03/2021

Why it was recalled

Presence of Particulate Matter - found in reserve sample vials at the firm.

Recalling firm

Firm
Fresenius Kabi USA, LLC
Notification channel
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Type
Voluntary: Firm initiated
Address
3 Corporate Dr, N/A, Lake Zurich, Illinois 60047-8930

Distribution

Quantity
3,497,575 vials
Distribution pattern
USA Nationwide and Puerto Rico

Timeline

Recall initiated
2020-04-20
FDA classified
2020-06-08
Posted by FDA
2020-06-17
Terminated
2023-10-16
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1297-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Ketorolac Tromethamine · FDA Drug Recalls